Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374565 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
A Phase 2 study of Pneumonia and SARS-CoV-2, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT04374565: Completed Phase 2 study of Pneumonia and SARS-CoV-2, sponsored by University of Virginia.
NCT04374565 is a Phase 2 study of Pneumonia and SARS-CoV-2 that has completed, run by University of Virginia. The registered enrollment target is 29 participants, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04374565, a Phase 2 study of Pneumonia and SARS-CoV-2, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A total of 29 eligible subjects will be enrolled to receive anti-SARS-CoV-2 plasma.Outcomes will be compared to hospitalized controls with confirmed COVID-19 disease through retrospective chart review.
Primary Outcome
Will be done by comparing the admission rate to the ICU between patients who received convalescent plasma and a control group who did not enroll in the study, or receive another experimental therapy.
Conditions Studied
Interventions
- DRUG High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Study Locations (2)
Virginia
- University of Virginia Medical Center - Charlottesville
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2021-03-05 |
| Phase | Phase 2 |
What the finished NCT04374565 record still lists
NCT04374565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 4,519-participant average among 47 other Pneumonia trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma is the first listed.
NCT04374565 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04374565 about?
NCT04374565 is a clinical study titled "Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia". This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial COVID-19 pneumonia by chest Xray or CT. A total of 29 eligible subjects will b...
What is the current status of trial NCT04374565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2020-05-05. Estimated completion is 2021-03-05.
What conditions does trial NCT04374565 study?
This clinical trial studies the following conditions: Pneumonia, SARS-CoV-2, Corona Virus Infection, SARS Pneumonia.
What interventions are being tested in trial NCT04374565?
The interventions under investigation include: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma (DRUG).
Who is sponsoring clinical trial NCT04374565?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04374565 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04374565's enrollment target sits among peer trials
29 43rd of 47 higher than 5 of 47 other Pneumonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pneumonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Individualizing Corticosteroid Use in Pneumonia
RECRUITING · Phase 2
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
ACTIVE NOT RECRUITING · Phase 2
-
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
COMPLETED · Phase 2
-
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
COMPLETED · Phase 2
-
Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI